Interleukin-6 concentration in the transgenic pig's liver preserved for 24 hours in Biolasol solution.
BACKGROUND
Increasing the human lifespan contributes to a higher number of patients with end-stage organ failure, which in turn stimulates the search for alternative sources. Xenotransplantation seems to be a promising approach in this respect.


OBJECTIVE
Analysis of changes in interleukin (IL)-6 concentration during 24-hour preservation of transgenic swine livers, depending on the kind of transgenesis and preservation solution used.


METHODS
The experiment was carried out in swine livers with transferred human genes that were divided into 5 groups. The following human genes were transferred: α1,2-fucosyltransferase (group I and II), α-galactosidase (III), combined α1,2-fucosyltransferase/α-galactosidase transgene (IV), and livers without modification (V). The livers were perfused and subsequently stored for 24 hours in Ringer's (group I) or Biolasol solutions (II-V). Reflush was then performed. IL-6 concentration was analyzed in the solution samples collected at the beginning and end of perfusion, and after 24 hours of preservation. ELISA was used to evaluate IL-6 concentration.


RESULTS
In liver homogenates from group I, IL-6 concentration after 24 hours of preservation increased by 8.24% compared to the levels observed after perfusion, whereas in the other groups IL-6 concentration decreased. The most significant decrease, 49.51%, was observed in group II; the least significant in group IV, 10.72%. In case of supernatants, a statistically significant increase of AUC0-30min level in relation to perfusion was observed in every group after 24-hour preservation and reperfusion. The highest values of AUC0-30min were observed in group I (α1,2-fucosyltransferase, Ringer's solution).


CONCLUSIONS
The study indicates the hepatoprotective action of Biolasol solution.
Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland. Electronic address: gregorydr@wp.pl.
G
G
Budziński
Department of Histology and Embryology, Medical University of Silesia, Katowice, Poland.
A
A
Suszka-Świtek
Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland.
P
P
Roman
Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland.
A
A
Caban
Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland.
G
G
Oczkowicz
Department of Pathomorphology, Medical University of Silesia, Katowice, Poland.
A
A
Wiaderkiewicz
Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland.
A
A
Mały
Department of Histology and Embryology, Medical University of Silesia, Katowice, Poland.
R
R
Wiaderkiewicz
The National Research Institute of Animal Production in Kraków-Balice, Poland.
Z
Z
Smorąg
"Biochefa" Pharmaceutical Research Production Plant, Sosnowiec, Poland.
F
F
Ryszka
Department of General, Vascular and Transplant Surgery, Medical University of Silesia, Katowice, Poland.
L
L
Cierpka
D000818:Animals; D030801:Animals, Genetically Modified; D005647:Fucosyltransferases / Q000235:genetics*; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D007552:Isotonic Solutions; D008099:Liver / Q000378:metabolism*; D009926:Organ Preservation / Q000379:methods; D019188:Organ Preservation Solutions; D010477:Perfusion; D015424:Reperfusion; D000077331:Ringer's Solution; D013552:Swine; D000519:alpha-Galactosidase / Q000235:genetics*
D015850:Interleukin-6; D007552:Isotonic Solutions; D019188:Organ Preservation Solutions; D000077331:Ringer's Solution; D005647:Fucosyltransferases; D000519:alpha-Galactosidase